Cephalon sees enough POC

Undeterred by a couple of missed primary endpoints, Cephalon Inc. announced last week it will exercise an option to acquire Ception Therapeutics Inc. for $250 million. Cephalon says a Phase II trial of Ception's Cinquil reslizumab, plus a study by the mAb's prior owner, provided sufficient evidence of clinical effect in eosinophilic asthma to justify moving forward.

"This proof-of-concept study was designed to see if the drug showed a treatment effect and had a favorable safety profile. Ample evidence for both was provided," Cephalon EVP and CMO Lesley Russell told BioCentury...